Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Signs Licensing Deal With ADC


Dallas, Texas 11/07/2013 (Financialstrend) – The micro mini caped, biotech firm Five Prime Therapeutics, Inc. (NASDAQ:FPRX) has just about completed one month of trading on the browsers. While it is still initial days the firm has attracted lot of attention from rating agencies who have been bullish about the prospects of the stock.

In an announcement geared to support the bullishness about the stock, the firm announced on November 5 that it has entered into a licensing deal with cancer drug maker ADC Therapeutics Sarl (‘ADC Therapeutics’). As part of the deal, Auven will initiate clinical trials to test out target drugs for cancer related ailments by using antibodies that it has licensed from Five Prime. ADC specializes in developing cures which combine antibodies with “pyrrolobenzodiazepine” based target drugs.

Commenting about the licensing deal, Lewis Williams who is the president and chief executive officer of Five Prime is quoted as saying, ”ADC Therapeutics is a leader in developing proprietary antibody-drug conjugates targeting major cancers such as breast, lung, prostate, renal and blood. We believe that antibodies directed toward this protein target, which is found on a variety of tumour types, will be most efficacious when armed with a cytotoxic drug conjugate. This strategic license allows us to progress a program by leveraging Five Prime’s strength in the development of novel biologic products and ADCT’s complementary strength in arming antibodies for use in treating cancer.”

The clinical stage firm has developed an exhaustive portfolio of close to 5,600 “human extracellular proteins”. Using its patented methods the firm identifies new targets from is list to explore possibilities of developing effective protein therapeutics. The firm has marshelled market cap of $13.26 million and accumulated net loss of $27 million in the past 12 months of its operations. Since its inception of public trading the stock has shed 18%  of its market value.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.